Table 3.

Primary study endpoint [composite of all-cause death, stroke, and major bleeding (International Society on Thrombosis and Haemostasis)] in the per-protocol and the modified intent-to-treat population

	Edoxaban (ITT N = 411)	VKA (ITT N = 203)	HR (95% CI)
PP population post-ablation a
N	316	101
Primary endpoint events, n (%)	1 (0.3)	2 (2.0)	0.16 (0.02–1.73)
PP population peri- and post-ablationb
N	316	101
Primary endpoint events, n (%)	4 (1.3)	3 (3.0)	0.42 (0.10–1.89)
mITT population peri- and post-ablation b
N	375	178
Primary endpoint events, n (%)	10 (2.7)	3 (1.7)	1.60 (0.44–5.78)

^aFrom the end of catheter ablation to day 90/end of treatment.

^bFrom the start of catheter ablation to day 90/end of treatment.

CI, confidence interval; HR, hazard ratio; mITT, modified intent-to-treat; PP, per-protocol; VKA, vitamin K antagonist.